OR WAIT null SECS
September 04, 2019
In a Phase III trial for advanced small-cell lung cancer, the investigational antibody drug conjugate, Rova-T (rovalpituzumab tesirine), did not demonstrate a survival benefit for patients taking it.
The company has received breakthrough therapy designation for its prophylactic respiratory syncytial virus vaccine candidate for treating adults aged 60 years or older.
Vertex will use the acquisition to develop cell-based treatments for type 1 diabetes.
August 15, 2019
The European Commission has approved an extension of the use of Dupixent (dupilumab) within the EU to include patients aged 12 to 17 years old with moderate-to-severe atopic dermatitis.
August 08, 2019
South Korea’s pharma/biotech space is projected to grow to $23.2 billion by 2022, and will likely attract foreign investment, according to a new market report by GlobalData.
August 02, 2019
As vaccines gain prominence within pharma, there is an expectation that specialized CDMO services will provide opportunities.
Protein characterization is a critical part of drug development, but as there are still limitations with available techniques, industry needs to look at technological advances to meet the specific requirements of complex molecule characterization.
As patient-centered therapies and clinical trials become more important, innovation is providing more control and transparency in the way that pharmaceuticals are delivered.
August 01, 2019
Industry experts discuss the role of gene-editing techniques in regenerative medicine and cell-line development.
Biopharma industry faces production challenges as gene therapies move from clinical to commercialization.